TGF-β pathway as a therapeutic target in bone metastases

Current Pharmaceutical Design

Volumn 16, Issue 11, 2010, Pages 1301-1312

  Juárez, Patricia ^a   Guise, Theresa A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Bone; Bone metastases; Breast cancer; Melanoma; Metastases; Prostatic cancer; TGF ; TGF inhibitors; TGF receptors

Indexed keywords

2 METHOXYESTRADIOL; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ANGIOGENESIS INHIBITOR; ANTIFIBROTIC AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AP 11014; AP 12009; BISPHOSPHONIC ACID DERIVATIVE; GC 1008; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KI 26894; LERDELIMUMAB; LY 2109761; LY 2157299; LY 580276; METELIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1D11; MONOCLONAL ANTIBODY 2G7; PEPTIDE 144; PF 03446962; SD 093; SD 208; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; [3 (PYRIDINE 2 YL) 4 (4 QUINONYL)] 1H PYRAZOLE;

ADVANCED CANCER; ANGIOGENESIS; ASTROCYTOMA; BONE ATROPHY; BONE METASTASIS; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER REGRESSION; CANCER SURVIVAL; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG TARGETING; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; GLIOBLASTOMA; GLIOMA; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SCAR; SCLERODERMA; SKIN FIBROSIS; SOLID TUMOR; SYSTEMIC SCLEROSIS; UNSPECIFIED SIDE EFFECT;

EID: 77950878893     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791034049     Document Type: Review

References (134)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
3. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103: 197-206. (Pubitemid 29053137)
4. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000; 88: 2979-2988. (Pubitemid 30413180)
5. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954-10959. (Pubitemid 37140134)
6. Coleman RE. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009; 45: 1909-1915.
7. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-1123.
8. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon- Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549. (Pubitemid 36808649)
9. Massague J. TGFβ in Cancer. Cell 2008; 134: 215-230.
10. Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem 2007; 102: 1333-1342.
11. Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
12. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor in human disease. N Engl J Med 2000; 342: 1350-1358. (Pubitemid 30408720)
13. Feng XH, Derynck R. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693. (Pubitemid 41740650)
14. Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700. (Pubitemid 36724933)
15. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003; 425: 577-584. (Pubitemid 37280136)
16. Massague J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
17. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997; 89: 1165-1173.
18. Lopez-Casillas F, Wrana JL, Massague J. glycan presents ligand to the TGF β signaling receptor. Cell 1993; 73: 1435-1444.
19. Lopez-Casillas F, Payne HM, Andres JL, Massague J. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 1994; 124: 557-568.
20. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, et al. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 2004; 23: 4018-4028.
21. Stover DG, Bierie B, Moses HL. A delicate balance: TGF-β and the tumor microenvironment. J Cell Biochem 2007; 101: 851-861.
22. Siegel PM, Shu W, Massague J. Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-β-mediated epithelial cell growth suppression. J Biol Chem 2003; 278: 35444-35450.
23. Zavadil J, Bitzer M, Liang D, Yang YC, Massimi A, Kneitz S, et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc Natl Acad Sci USA 2001; 98: 6686-6691.
24. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12: 27-36.
25. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13: 902-914. (Pubitemid 34250354)
26. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129. (Pubitemid 32952643)
27. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807-821. (Pubitemid 37376979)
28. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 1996; 7: 93-102.
29. Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Roberts AB, et al. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 1994; 91: 8772-8776.
30. Ohue M, Tomita N, Monden T, Miyoshi Y, Ohnishi T, Izawa H, et al. Mutations of the transforming growth factor β type II receptor gene and microsatellite instability in gastric cancer. Int J Cancer 1996; 68: 203-206. (Pubitemid 26380124)
31. Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Tomita N, et al. Microsatellite instability and mutated type II transforming growth factor-β receptor gene in gliomas. Cancer Lett 1997; 112: 251-256. (Pubitemid 27104303)
32. Chen T, Carter D, Garrigue-Antar L, Reiss M. Transforming growth factor β type I receptor kinase mutant associated with metastatic breast cancer. Cancer Res 1998; 58: 4805-4810. (Pubitemid 28503673)
33. Chen T, Triplett J, Dehner B, Hurst B, Colligan B, Pemberton J, et al. Transforming growth factor-β receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 2001; 61: 4679-4682. (Pubitemid 32691875)
34. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58: 5329-5332. (Pubitemid 28551110)
35. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor β type I receptor abolishes growth regulation by transforming growth factor β in a cutaneous T-cell lymphoma. Blood 1999; 94: 2854-2861. (Pubitemid 29477314)
36. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MADrelated protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543-552. (Pubitemid 26299486)
37. Takagi Y, Koumura H, Futamura M, Aoki S, Ymaguchi K, Kida H, et al. Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer 1998; 78: 1152-1155. (Pubitemid 28479142)
38. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999; 18: 4879-4883. (Pubitemid 29423571)
39. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353. (Pubitemid 3021510)
40. Gold LI. The role for transforming growth factor-β (TGF-β) in human cancer. Crit Rev Oncog 1999; 10: 303-360.
41. Ananth S, Knebelmann B, Gruning W, Dhanabal M, Walz G, Stillman IE, et al. Transforming growth factor β 1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 1999; 59: 2210-2216.
42. Rowland-Goldsmith MA, Maruyama H, Matsuda K, Idezawa T, Ralli M, Ralli S, et al. Soluble type II transforming growth factor-β receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 2002; 1: 161-167.
43. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop Relat Res 1991: 30-48.
44. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-β from bone matrix. J Biol Chem 2002; 277: 21352-21360.
45. Balooch G, Balooch M, Nalla RK, Schilling S, Filvaroff EH, Marshall GW, et al. TGF-β regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA 2005; 102: 18813-18818.
46. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, et al. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE 2009; 4: e5275.
47. Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-β 1 to the bone. Endocr Rev 2005; 26: 743-774.
48. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-β1- induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 2009; 15: 757-765.
49. Hering S, Isken E, Knabbe C, Janott J, Jost C, Pommer A, et al. TGFβ1 and TGFβ2 mRNA and protein expression in human bone samples. Exp Clin Endocrinol Diabetes 2001; 109: 217-226.
50. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI. Immunohistochemical localization of TGF β 1, TGF β 2, and TGF β 3 in the mouse embryo: expression patterns suggest multiple roles during embryonic development. J Cell Biol 1991; 115: 1091-1105.
51. Thompson NL, Flanders KC, Smith JM, Ellingsworth LR, Roberts AB, Sporn MB. Expression of transforming growth factor-β 1 in specific cells and tissues of adult and neonatal mice. J Cell Biol 1989; 108: 661-669.
52. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-β- induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J 2001; 20: 2254-2272.
53. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 2004; 23: 552-563.
54. Karsdal MA, Andersen TA, Bonewald L, Christiansen C. Matrix metalloproteinases (MMPs) safeguard osteoblasts from apoptosis during transdifferentiation into osteocytes: MT1-MMP maintains osteocyte viability. DNA Cell Biol 2004; 23: 155-165.
55. Hattersley G, Chambers TJ. Effects of transforming growth factor 1 on the regulation of osteoclastic development and function. J Bone Miner Res 1991; 6: 165-172.
56. Dieudonne SC, Foo P, van Zoelen EJ, Burger EH. Inhibiting and stimulating effects of TGF-β 1 on osteoclastic bone resorption in fetal mouse bone organ cultures. J Bone Miner Res 1991; 6: 479-487.
57. Lerner UH. Transforming growth factor-β stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway. J Bone Miner Res 1996; 11: 1628-1639.
58. Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, Turner CH. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-β1 gene. Bone 1998; 23: 87-93. (Pubitemid 28379868)
59. Atti E, Gomez S, Wahl SM, Mendelsohn R, Paschalis E, Boskey AL. Effects of transforming growth factor-β deficiency on bone development: a Fourier transform-infrared imaging analysis. Bone 2002; 31: 675-684. (Pubitemid 36092090)
60. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, et al. TGF 2β knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 1997; 124: 2659-2670. (Pubitemid 27341765)
61. Proetzel G, Pawlowski SA, Wiles MV, Yin M, Boivin GP, Howles PN, et al. Transforming growth factor-β 3 is required for secondary palate fusion. Nat Genet 1995; 11: 409-414. (Pubitemid 3007193)
62. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 2001; 20: 1663-1673. (Pubitemid 32299403)
63. Baffi MO, Slattery E, Sohn P, Moses HL, Chytil A, Serra R. Conditional deletion of the TGF-β type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones. Dev Biol 2004; 276: 124-142. (Pubitemid 39452851)
64. Coleman RE, Seaman JJ. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol 2001; 28: 11-16.
65. Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis 2002; 5: 264-272. (Pubitemid 36124436)
66. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
67. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Lowik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001; 16: 1077-1091. (Pubitemid 32467152)
68. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-573.
69. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PF, Spillane JB, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 2006; 66: 2250-2256. (Pubitemid 43294937)
70. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451-4458. (Pubitemid 30666108)
71. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996; 98: 1544-1549. (Pubitemid 26327863)
72. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, et al. Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002; 277: 24571-24578.
73. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev 2009; 23: 1882-1894.
74. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, et al. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009; 4: e6896.
75. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005; 102: 13909-13914.
76. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007; 67: 2317-2324.
77. Korpal M, Yan J, Lu X, Xu S, Lerit DA, Kang Y. Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med 2009; 15: 960-966.
78. Dasch JR, Pace DR, Waegell W, Inenaga D, Ellingsworth L. Monoclonal antibodies recognizing transforming growth factor-β. Bioactivity neutralization and transforming growth factor β 2 affinity purification. J Immunol 1989; 142: 1536-1541.
79. Thompson JE, Vaughan TJ, Williams AJ, Wilton J, Johnson KS, Bacon L, et al. A fully human antibody neutralising biologically active human TGFβ2 for use in therapy. J Immunol Methods 1999; 227: 17-29.
80. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-β2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 1999; 40: 2225-2234.
81. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-1022.
82. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-β2 antibody as a new postoperative anti- scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003; 44: 3394-3401.
83. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824.
84. Morris JC, Shapiro GI, Tan AR, Lawrence DP, Olencki TE, Dezube BJ, et al. Phase I/II Study of GC1008: A human antitransforming growth factor-β (TGF-β) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J Clin Oncol 2008; 26: 9028.
85. Genzyme. Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma. In:ClinicalTrials.gov [Internet]. Bethesda (MD): National library of Medicine (US). 2006- [Accessed on 2009 Nov 25]. Available from: http:// clinicaltrials.gov/show/NCT00356460. NLM Identifier: NCT00356460.
86. Jersey CIoN. Effects of monoclonal antibody GC1008 in blood samples from patients with unresectable locally advanced or metastatic kidney cancer or malignant melanoma treated on clinical trial NCI-06-C-0200. Bethesda (MD): National library of Medicine (US). 2008- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/NCT00899444. NLM Identifier: NCT00899444.
87. Genzyme. Safety study of GC1008 in patients with focal segmental glomerulosclerosis (FSGS) of single doses of GC1008 in patients with treatment resistant idiopathic FSGS. In:ClinicalTrials.gov [Internet]. Bethesda (MD): National library of Medicine (US). 2007- [Accessed on 2009 Nov 25]. Available from: http:// clinicaltrials.gov/show/NCT00464321. NLM Identifier: NCT00464321.
88. Genzyme. Study of GC1008 in patients with idiopathic pulmonary fibrosis (IPF). In:ClinicalTrials.gov[Internet]. Bethesda (MD): National library of Medicine (US). 2005- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/NCT00125385. NLM Identifier: NCT00125385.
89. Arteaga CL, Carty-Dugger T, Moses HL, Hurd SD, Pietenpol JA. Transforming growth factor β 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differ 1993; 4: 193-201.
90. Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression. J Clin Invest 1993; 92: 2569-2576.
91. Mancuso P, Shalinsky DR, Calleri A, Quarna J, Antoniotti P, Jilani I, et al. Evaluation of ALK-1 expression in circulating endothelial cells (CECs) as an exploratory biomarker for PF-03446962 undergoing phase I trial in cancer patients. J Clin Oncol 2009; 27:15s: abstr 3573.
92. Pfizer. A First In Patient, Study Of Investigational Drug PF- 03446962. In: Patients With Advanced Solid Tumors. In:ClinicalTrials.gov[Internet]. Bethesda (MD): National library of Medicine (US). 2007- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/NCT00557856. NLM Identifier: NCT00557856.
93. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551-1559.
94. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109: 1607-1615.
95. Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L. A soluble transforming growth factor β type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB- 231 cells. Cancer Res 1999; 59: 5041-5046.
96. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, et al. Antitumor activity of a recombinant βsoluble glycan in human breast cancer xenograft. Cancer Res 2002; 62: 4690-4695.
97. Serrati S, Margheri F, Pucci M, Cantelmo AR, Cammarota R, Dotor J, et al. TGF 1 antagonistic peptides inhibit TGFβ1-dependent angiogenesis. Biochem Pharmacol 2009; 77: 813-825.
98. ISDIN. Efficacy and safety study of p144 to treat skin fibrosis in systemic sclerosis. In:ClinicalTrials.gov[Internet]. Bethesda (MD): National library of Medicine (US). 2007- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/NCT00574613. NLM Identifier: NCT00574613.
99. Arteaga CL. Inhibition of TGFβ signaling in cancer therapy. Curr Opin Genet Dev 2006; 16: 30-37.
100. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptorlike kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002; 62: 65-74.
101. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, et al. Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 2002; 62: 58-64.
102. Matsuyama S, Iwadate M, Kondo M, Saitoh M, Hanyu A, Shimizu K, et al. SB-431542 and Gleevec inhibit transforming growth factor-β-induced proliferation of human osteosarcoma cells. Cancer Res 2003; 63: 7791-7798.
103. Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, et al. Targeting endogenous transforming growth factor β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res 2004; 64: 5200-5211.
104. Peng SB, Yan L, Xia X, Watkins SA, Brooks HB, Beight D, et al. Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 2005; 44: 2293-2304. (Pubitemid 40279534)
105. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954-7961. (Pubitemid 39446929)
106. Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, et al. Inhibition of transforming growth factor β signaling reduces pancreatic adenocarcinoma growth and invasiveness. Mol Pharmacol 2007; 72: 152-161. (Pubitemid 46998534)
107. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-2914.
108. Fakhrai H, Mantil JC, Liu L, Nicholson GL, Murphy-Satter CS, Ruppert J, et al. Phase I clinical trial of a TGF-β antisensemodified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006; 13: 1052-1060.
109. Pharma A. Safety and tolerability of AP 12009, administered I.V. in patients with advanced tumors known to overproduce TGF-β-2. In:ClinicalTrials.gov[Internet]. Bethesda (MD): National library of Medicine (US). 2009- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials. gov/show/NCT00844064. NLM Identifier: NCT00844064.
110. Pharma A. Phase IIb clinical trial with TGF-β2 antisense compound AP 12009 for recurrent or refractory high-grade glioma. In:ClinicalTrials. gov[Internet]. Bethesda (MD): National library of Medicine (US). 2007- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/NCT00431561. NLM Identifier: NCT00431561.
111. Pharma A. Efficacy and safety of AP 12009 in patients with recurrent or refractory anaplastic astrocytoma (SAPPHIRE). In: ClinicalTrials.gov[Internet]. Bethesda (MD): National library of Medicine (US). 2008- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/NCT00761280. NLM Identifier: NCT00761280.
112. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, et al. Inhibition of TGF-β2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17: 201-212.
113. Gradalis I. Phase I trial of TGFB2-antisense-GMCSF gene modified autologous tumor cell (TAG) Vaccine for Advanced Cancer (Auto TAG). In: ClinicalTrials.gov[Internet]. Bethesda (MD): National library of Medicine (US). 2008- [Accessed on 2009 Nov 25]. Available from: http://clinicaltrials.gov/show/ NCT 00684294. NLM Identifier: NCT00684294.
114. Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest 2002; 110: 1559-1572.
115. Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G, et al. The tumor suppressor Smad4 is required for transforming growth factor -induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006; 66: 2202-2209.
116. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, et al. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007; 98: 127-133.
117. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem 2003; 46: 3953-3956.
118. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res 2006; 66: 6714-6721.
119. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo. Clin Cancer Res 2006; 12: 4315-4330.
120. Stebbins EG, Mohammad KS, Niewolna M, McKenna CR, Mison AP, Schimmoller F, et al. SD-208, a small molecule inhibitor of transforming growth factor β receptor I kinase reduces breast cancer metastases to bone and improves survival in a mouse model. J Bone Miner Res 2005; 20: 1216 (abstract).
121. Biswas S, Wilburn C, Munoz SA, Sterling JA, Lonning S, Mundy GR. Monoclonal antibody to transforming growth factor inhibits tumor burden and osteolysis in a pre-clinical model of bone metastasis. J Bone Miner Res 2008; 23.
122. Juarez P, Chirgwin J, Mohammad KS, Ryan C, Walton H, Niewolna M, et al. Halofuginone decreases osteolytic bone metastases. J Bone Miner Res 2009; 24.
123. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 2007; 67: 8742-8751.
124. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007; 171: 1047-1057.
125. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T, et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008; 27: 6322-6333.
126. Mohammad KS, Stebbins EG, Kingsley L, Fournier PGJ, Niewolna M, McKenna CR, et al. Combined transforming growth factor β receptor I kinase inhibitor and biphosphonates are additve to reduce breast cancer bone metastases. J Bone Miner Res 2008; 23: F275(Abstract).
127. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699.
128. Ruzek MC, Hawes M, Pratt B, McPherson J, Ledbetter S, Richards SM, et al. Minimal effects on immune parameters following chronic anti-TGF-β monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 2003; 25: 235-257.
129. Calvo-Aller E, Baselga J, Glatt S, Cleverly A, Lahn M, Arteaga CL, Rothenberg ML, et al. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-β receptor I kinase. J Clin Oncol 2008; 26: 14554 (abstract).
130. Bogdahn U, Mahapatra AK, Olyushin V, Parfenov V, Stockhammer G, Ludwig S, et al. Results of a phase Iib activecontrolled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma. J Clin Oncol 2008; 20: 2076 (abstract).
131. Siriwardena D, Khaw PT, King AJ, Donaldson ML, Overton BM, Migdal C, et al. Human antitransforming growth factor β (2) monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 2002; 109: 427-431.
132. Fernandez-Gamba A, Leal MC, Morelli L, Castano EM. Insulindegrading enzyme: structure-function relationship and its possible roles in health and disease. Curr Pharm Des 2009; 15(31): 3644-3655.
133. Hospers GA, Helmond FA, de Vries EG, Dierckx RA, de Vries EF. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 2008; 14(28): 3020-3032.
134. Tuttolomondo A, Di Raimondo D, di Sciacca R, Pinto A, Licata G. Inflammatory cytokines in acute ischemic stroke. Curr Pharm Des 2008; 14(33): 3574-3589.